Can Baseline [18F]FDG PET/CT Predict Response to Immunotherapy After 6 Months and Overall Survival in Patients with Lung Cancer or Malignant Melanoma? A Multicenter Retrospective Study
Andrea Bianchi,Maria Luisa De Rimini,Rosa Sciuto,Alessio Annovazzi,Silvia Di Traglia,Matteo Bauckneht,Francesco Lanfranchi,Silvia Morbelli,Anna Giulia Nappi,Cristina Ferrari,Giuseppe Rubini,Stefano Panareo,Luca Urso,Mirco Bartolomei,Davide D'Arienzo,Tullio Valente,Virginia Rossetti,Paola Caroli,Federica Matteucci,Demetrio Aricò,Michelangelo Bombaci,Domenica Caponnetto,Francesco Bertagna,Domenico Albano,Francesco Dondi,Sara Gusella,Alessandro Spimpolo,Cinzia Carriere,Michele Balma,Ambra Buschiazzo,Rosj Gallicchio,Giovanni Storto,Livia Ruffini,Maura Scarlattei,Giorgio Baldari,Anna Rita Cervino,Lea Cuppari,Marta Burei,Giuseppe Trifirò,Elisabetta Brugola,Carolina Arianna Zanini,Alessandra Alessi,Valentina Fuoco,Ettore Seregni,Désirée Deandreis,Virginia Liberini,Antonino Maria Moreci,Salvatore Ialuna,Sabina Pulizzi,Laura Evangelista
DOI: https://doi.org/10.1089/cbr.2022.0092
Abstract:Aim: To assess the role of baseline 18F-fluorodeoxyglucose ([18F]FDG)-positron emission tomography/computed tomography (PET/CT) in predicting response to immunotherapy after 6 months and overall survival (OS) in patients with lung cancer (LC) or malignant melanoma (MM). Materials and Methods: Data from a multicenter, retrospective study conducted between March and November 2021 were analyzed. Patients >18 years old with a confirmed diagnosis of LC or MM, who underwent a baseline [18F]FDG-PET/CT within 1-2 months before starting immunotherapy and had a follow-up of at least 12 months were included. PET scans were examined visually and semiquantitatively by physicians at peripheral centers. The metabolic tumor burden (number of lesions with [18F]FDG-uptake) and other parameters were recorded. Clinical response was assessed at 3 and 6 months after starting immunotherapy, and OS was calculated as the time elapsing between the PET scan and death or latest follow-up. Results: The study concerned 177 patients with LC and 101 with MM. Baseline PET/CT was positive in primary or local recurrent lesions in 78.5% and 9.9% of cases, in local/distant lymph nodes in 71.8% and 36.6%, in distant metastases in 58.8% and 84%, respectively, in LC and in MM patients. Among patients with LC, [18F]FDG-uptake in primary/recurrent lung lesions was more often associated with no clinical response to immunotherapy after 6 months than in cases without any tracer uptake. After a mean 21 months, 46.5% of patients with LC and 37.1% with MM had died. A significant correlation emerged between the site/number of [18F]FDG foci and death among patients with LC, but not among those with MM. Conclusions: In patients with LC who are candidates for immunotherapy, baseline [18F]FDG-PET/CT can help to predict response to this therapy after 6 months, and to identify those with a poor prognosis based on their metabolic parameters. For patients with MM, there was only a weak correlation between baseline PET/CT parameters, response to therapy, and survival.